[go: up one dir, main page]

MA30428B1 - Derives de dihydropyrazolopyrimidinones - Google Patents

Derives de dihydropyrazolopyrimidinones

Info

Publication number
MA30428B1
MA30428B1 MA31411A MA31411A MA30428B1 MA 30428 B1 MA30428 B1 MA 30428B1 MA 31411 A MA31411 A MA 31411A MA 31411 A MA31411 A MA 31411A MA 30428 B1 MA30428 B1 MA 30428B1
Authority
MA
Morocco
Prior art keywords
group
formula
compounds represented
alkyl group
dihydropyrazolopyrimidinones
Prior art date
Application number
MA31411A
Other languages
English (en)
Inventor
Toshihiro Sakamoto
Satoshi Sunami
Fuyuki Yamamoto
Kenji Niiyama
Makoto Bamba
Keiji Takahashi
Takeshi Sagara
Sachie Otsuki
Toshihide Nishibata
Takashi Yoshizumi
Hiroshi Hirai
Hidetomo Furuyama
Original Assignee
Banyu Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38655640&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA30428(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Banyu Pharma Co Ltd filed Critical Banyu Pharma Co Ltd
Publication of MA30428B1 publication Critical patent/MA30428B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

L'INVENTION A TRAIT À DES COMPOSÉS REPRÉSENTÉS PAR LA FORMULE (I), DANS LAQUELLE : A1 EST SÉLECTIONNÉ PARMI LES COMPOSÉS REPRÉSENTÉS PAR LA FORMULE (AA1); R1 REPRÉSENTE UN GROUPE ALCÉNYLE INFÉRIEUR OU UN GROUPE ALCYNYLE INFÉRIEUR; R2 REPRÉSENTE UN GROUPE PHÉNYLE, PYRIDYLE OU THIÉNYLE; R5 ET R6 REPRÉSENTENT UN ATOME D'HYDROGÈNE, UN GROUPE ALKYLE INFÉRIEUR OU UN GROUPE HYDROXY ALKYLE INFÉRIEUR, ETC. LES COMPOSÉS SELON L'INVENTION PRÉSENTENT UN EFFET INHIBITEUR DE LA KINASE WEE1 ET SONT DONC UTILES DANS LE DOMAINE MÉDICAL, NOTAMMENT POUR LE TRAITEMENT DE DIVERS CANCERS.
MA31411A 2006-04-27 2008-11-24 Derives de dihydropyrazolopyrimidinones MA30428B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2006124208 2006-04-27

Publications (1)

Publication Number Publication Date
MA30428B1 true MA30428B1 (fr) 2009-05-04

Family

ID=38655640

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31411A MA30428B1 (fr) 2006-04-27 2008-11-24 Derives de dihydropyrazolopyrimidinones

Country Status (38)

Country Link
US (4) US7834019B2 (fr)
EP (2) EP2016080B1 (fr)
JP (2) JP4513919B2 (fr)
KR (1) KR101409161B1 (fr)
CN (1) CN101432284B (fr)
AR (1) AR060635A1 (fr)
AT (1) ATE475662T1 (fr)
AU (1) AU2007244185B2 (fr)
BR (1) BRPI0710081A2 (fr)
CA (1) CA2650119C (fr)
CR (1) CR10359A (fr)
CY (2) CY1111069T1 (fr)
DE (1) DE602007008085D1 (fr)
DK (2) DK2017278T3 (fr)
DO (1) DOP2007000084A (fr)
EC (1) ECSP088812A (fr)
ES (2) ES2348751T3 (fr)
GT (1) GT200800211A (fr)
HN (1) HN2008001532A (fr)
HR (2) HRP20161763T1 (fr)
HU (1) HUE032987T2 (fr)
IL (1) IL194367A (fr)
LT (1) LT2017278T (fr)
MA (1) MA30428B1 (fr)
MX (1) MX2008013063A (fr)
MY (1) MY145408A (fr)
NO (1) NO341617B1 (fr)
NZ (1) NZ571196A (fr)
PE (1) PE20080695A1 (fr)
PL (2) PL2016080T3 (fr)
PT (2) PT2016080E (fr)
RU (1) RU2437885C2 (fr)
SI (2) SI2016080T1 (fr)
SV (1) SV2009003060A (fr)
TW (1) TWI409262B (fr)
UA (1) UA96152C2 (fr)
WO (2) WO2007126128A1 (fr)
ZA (1) ZA200807748B (fr)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR060635A1 (es) 2006-04-27 2008-07-02 Banyu Pharma Co Ltd Derivados de 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-ona, composiciones farmaceuticas que los comprenden y su uso en el tratamiento del cancer
JP5411847B2 (ja) * 2007-04-25 2014-02-12 Ｍｓｄ株式会社 Ｗｅｅｌキナーゼインヒビターとしてのジヒドロピラゾロピリミジノン誘導体の多形
WO2008141385A1 (fr) * 2007-05-21 2008-11-27 Biota Scientific Management Pty Ltd Inhibiteurs de polymérases virales
EP2213673B1 (fr) * 2007-10-23 2013-06-05 Msd K.K. Dérivé de dihydropyrazolopyrimidinone substitué par pyridone
WO2009151997A1 (fr) * 2008-06-12 2009-12-17 Merck & Co., Inc. Procédé de production de dérivés de bicycloaniline
WO2010067888A1 (fr) 2008-12-12 2010-06-17 Banyu Pharmaceutical Co.,Ltd. Dérivés de dihydropyrimidopirymidine
WO2010076887A1 (fr) * 2009-01-05 2010-07-08 Banyu Pharmaceutical Co.,Ltd. Biomarqueurs prédictifs utiles pour une thérapie anticancéreuse à médiation par un inhibiteur de wee1
WO2010098367A1 (fr) * 2009-02-25 2010-09-02 Banyu Pharmaceutical Co.,Ltd. Dérivé de pyrimido-pyrimido-indazole
WO2011027800A1 (fr) * 2009-09-02 2011-03-10 Banyu Pharmaceutical Co.,Ltd. Utilisation de biomarqueur(s) pour identifier un patient répondant à l'inhibiteur de wee1 et méthodes de traitement du cancer à médiation par p53 dysfonctionnel ou adhérent par l'administration d'un inhibiteur de wee1
US8703779B2 (en) 2009-09-15 2014-04-22 Merck Sharp & Dohme Corp. Preparation of crystalline forms of dihydropyrazolopyrimidinone
CA2817968C (fr) 2010-11-16 2019-03-12 Array Biopharma Inc. Combinaison d'inhibiteurs de la checkpoint kinase 1 et d'inhibiteurs de la wee 1 kinase
EP3266764B1 (fr) * 2011-04-27 2019-01-09 Zeon Corporation Composé polymérisable, composition polymérisable, polymère et matériau optiquement anisotrope
US8796289B2 (en) 2011-07-19 2014-08-05 Abbvie Inc. Pyridazino[4,5-D]pyrimidin-5(6H)-one inhibitors of kinases
US9345705B2 (en) 2011-09-15 2016-05-24 Merck Sharp & Dohme Corp. Compositions and methods for treating cancer
WO2013059485A1 (fr) * 2011-10-20 2013-04-25 Abbvie Inc. Composés de pyridopyrimidinone inhibiteurs de kinases
US9718821B2 (en) * 2012-02-23 2017-08-01 Abbvie Inc. Pyridopyrimidinone inhibitors of kinases
WO2014062454A1 (fr) * 2012-10-15 2014-04-24 Merck Sharp & Dohme Corp. Compositions et procédés de traitement du cancer
AU2013352568B2 (en) 2012-11-28 2019-09-19 Merck Sharp & Dohme Llc Compositions and methods for treating cancer
WO2014168941A1 (fr) 2013-04-09 2014-10-16 Lixte Biotechnology, Inc. Formulations d'oxabicycloheptanes et d'oxabicycloheptènes
GB201306610D0 (en) * 2013-04-11 2013-05-29 Almac Discovery Ltd Pharmaceutical compounds
GB201322602D0 (en) 2013-12-19 2014-02-05 Almac Discovery Ltd Pharmaceutical compounds
EP3235505B1 (fr) * 2014-12-17 2020-05-06 Delta-Fly Pharma, Inc. Composition pharmaceutique pour le traitement ou la palliation d'un patient âgé atteint d'un cancer ou d'un patient atteint d'un cancer en phase terminale
AR104291A1 (es) 2015-04-17 2017-07-12 Abbvie Inc Moduladores tricíclicos de la señalización por tnf
UY36628A (es) 2015-04-17 2016-11-30 Abbvie Inc Indazolonas como moduladores de la señalización de tnf
EP3294726A1 (fr) 2015-04-17 2018-03-21 AbbVie Inc. Indazolones utilisées en tant que modulateurs de la signalisation du tnf
DK3345907T3 (da) * 2015-09-01 2020-06-22 Taiho Pharmaceutical Co Ltd Pyrazolo[3,4-d]pyrimidinforbindelser eller salte deraf
CN105130986B (zh) * 2015-09-30 2017-07-18 广州科擎新药开发有限公司 嘧啶或吡啶并吡啶酮类化合物及其应用
AU2016344040B2 (en) * 2015-11-01 2020-12-10 The Regents Of The University Of Colorado, A Body Corporate Wee 1 kinase inhibitors and methods of making and using the same
GB201612092D0 (en) 2016-07-12 2016-08-24 Almac Discovery Ltd Pharmaceutical compounds
CN110023290B (zh) 2016-09-15 2022-08-12 勃林格殷格翰国际有限公司 作为ripk2抑制剂的杂芳基甲酰胺化合物
CN106719769A (zh) * 2016-11-28 2017-05-31 山东农业大学 一种含香菇多糖、苯醚甲环唑和噻虫啉的病虫兼治农药组合物
MX2019006694A (es) 2016-12-08 2019-08-21 Lixte Biotechnology Inc Oxabicicloheptanos para la modulacion de la respuesta inmunitaria.
WO2018133829A1 (fr) 2017-01-23 2018-07-26 南京明德新药研发股份有限公司 Dérivé de 1,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-one utilisé en tant qu'inhibiteur de wee1
GB201703881D0 (en) * 2017-03-10 2017-04-26 Almac Discovery Ltd Pharmaceutical compounds
CN108623615B (zh) * 2017-03-23 2022-12-13 上海迪诺医药科技有限公司 吡唑[3,4-d]嘧啶-3-酮的大环衍生物、其药物组合物及应用
KR20190130621A (ko) 2017-03-31 2019-11-22 시애틀 지네틱스, 인크. Chk1 저해제와 wee1 저해제의 조합물
KR20200034781A (ko) 2017-08-01 2020-03-31 리커리엄 아이피 홀딩스, 엘엘씨 1,2-다이하이드로-3H-피라졸로[3,4-d]피리미딘-3-온 유사체
CN109422754A (zh) * 2017-08-24 2019-03-05 上海迪诺医药科技有限公司 吡唑并[3,4-d]嘧啶-3-酮衍生物、其药物组合物及应用
WO2019074981A1 (fr) 2017-10-09 2019-04-18 GiraFpharma LLC Composés hétérocycliques et leurs utilisations
EP3694861A4 (fr) * 2017-10-09 2021-05-19 Nuvation Bio Inc. Composés hétérocycliques et leurs utilisations
PT3712150T (pt) * 2017-11-01 2024-08-22 Wuxi Biocity Biopharmaceutics Co Ltd Composto macrocíclico que serve como inibidor wee1 e aplicações do mesmo
WO2019096322A1 (fr) * 2017-11-20 2019-05-23 上海医药集团股份有限公司 Composé de pyrazolone-pyrimidine, son procédé de préparation et son application
CN111315747B (zh) * 2018-01-05 2023-05-02 四川科伦博泰生物医药股份有限公司 二氢吡唑酮并嘧啶类化合物及其制备方法和用途
US11479555B2 (en) 2018-02-23 2022-10-25 Newave Pharmaceutical Inc. Substituted 1,2-dihydro-3H-pyrazolo[3,4-D]pyrimidin-3-ones as inhibitors of WEE-1 kinase
AU2019227823B2 (en) * 2018-02-28 2024-12-12 The Regents Of The University Of Colorado, A Body Corporate WEE1 kinase inhibitors and methods of treating cancer using the same
EP3762385B1 (fr) * 2018-03-09 2025-02-12 Recurium IP Holdings, LLC 1,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones substituées
CN108653282B (zh) * 2018-06-28 2020-08-14 中国科学院昆明植物研究所 苯并噻唑类及苯并吡咯类化合物在制备抗肿瘤药物中的应用
EP3875460A4 (fr) * 2018-10-26 2022-07-20 Wuxi Biocity Biopharmaceutics Co., Ltd. Dérivé de pyrimidopyrazolone en tant qu'inhibiteur de wee1 et son utilisation
CN111662283B (zh) * 2019-03-07 2021-11-16 湖南化工研究院有限公司 咪唑并吡啶类化合物及其中间体、制备方法与应用
JP2022528047A (ja) * 2019-03-22 2022-06-08 ショウヤオ ホールディングス（ベイジン） カンパニー， リミテッド Ｗｅｅ１阻害剤、その製造および用途
WO2020210380A1 (fr) * 2019-04-09 2020-10-15 Nuvation Bio Inc. Composés hétérocycliques et leurs utilisations
BR112021019703A2 (pt) 2019-04-09 2021-12-14 Nuvation Bio Inc Compostos heterocíclicos e usos dos mesmos
WO2020210320A1 (fr) * 2019-04-11 2020-10-15 Recurium Ip Holdings, Llc L,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones substituées
CN113784968B (zh) 2019-04-30 2024-03-15 无锡智康弘义生物科技有限公司 Wee1抑制剂化合物的晶型及其应用
CN112142748B (zh) 2019-06-28 2023-07-04 上海医药集团股份有限公司 一种吡唑酮并嘧啶类化合物、其制备方法及应用
MX2021015572A (es) 2019-06-28 2022-04-06 Shanghai Pharmaceuticals Holding Co Ltd Compuesto de pirazolopirimidina, método de preparación para el mismo y sus aplicaciones.
CN114599399A (zh) 2019-10-25 2022-06-07 阿斯利康(瑞典)有限公司 治疗癌症的方法
AU2020407573A1 (en) * 2019-12-20 2022-07-14 Recurium Ip Holdings, Llc Combinations
CN113387962A (zh) * 2020-03-12 2021-09-14 上海迪诺医药科技有限公司 吡唑并[3,4-d]嘧啶-3-酮衍生物、其药物组合物及应用
EP4169919A4 (fr) * 2020-06-17 2024-07-17 Wigen Biomedicine Technology (Shanghai) Co., Ltd. Dérivé de pyrazolo[3,4-d]pyrimidine-3-cétone utilisé en tant qu'inhibiteur de wee-1
KR102549484B1 (ko) * 2020-12-08 2023-06-29 한국화학연구원 피라졸로피리미딘 설폰아마이드 유도체 및 이를 유효성분으로 포함하는 암 관련 질환의 예방 또는 치료용 약학적 조성물
WO2022171128A1 (fr) * 2021-02-09 2022-08-18 微境生物医药科技(上海)有限公司 Dérivé de pyrazolo[3,4-d]pyrimidine-3-cétone servant d'inhibiteur de wee-1
CN116867787A (zh) * 2021-02-09 2023-10-10 微境生物医药科技(上海)有限公司 吡唑并[3,4-d]嘧啶-3-酮衍生物
WO2022171126A1 (fr) * 2021-02-09 2022-08-18 微境生物医药科技(上海)有限公司 Composé cyclique fusionné utilisé comme inhibiteur de wee-1
CN115197221B (zh) * 2021-04-02 2024-05-24 轩竹(北京)医药科技有限公司 二氢吡唑并嘧啶酮类大环衍生物及其用途
US20240252655A1 (en) 2021-04-29 2024-08-01 Novartis Ag Deubiquitinase-targeting chimeras and related methods
BR112023022236A2 (pt) 2021-04-30 2024-02-06 Wigen Biomedicine Tech Shanghai Co Ltd Composto de fórmula geral (1) ou seu isômero, forma cristalina, sal farmaceuticamente aceitável, hidrato ou solvato; composição farmacêutica; e; uso do composto ou seu isômero, forma cristalina, sal farmaceuticamente aceitável, hidrato ou solvato
AU2022280213A1 (en) 2021-05-28 2023-08-31 Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. Wee1 inhibitor and use thereof
TW202328142A (zh) * 2021-09-18 2023-07-16 香港商優領醫藥科技(香港)有限公司 含嘧啶并二氫吡唑啉酮類衍生物、其藥學上可接受的鹽及其製備方法和應用
CN113880844B (zh) * 2021-09-29 2023-02-14 武汉九州钰民医药科技有限公司 Wee1蛋白激酶抑制剂adavosertib的化学合成方法
CN113735863A (zh) * 2021-09-29 2021-12-03 武汉九州钰民医药科技有限公司 Wee1抑制剂adavosertib的制备工艺
TW202322812A (zh) * 2021-11-01 2023-06-16 大陸商正大天晴藥業集團股份有限公司 吡唑［３，４－ｄ］嘧啶－３－酮類化合物、包含其的藥物組合物及其醫藥用途
CN116462687B (zh) * 2022-01-18 2025-01-07 江苏天士力帝益药业有限公司 Wee1抑制剂及其制备和用途
CN116836184B (zh) * 2022-03-25 2025-07-25 药雅科技(上海)有限公司 Wee1激酶抑制剂的制备及其应用
CN115073460B (zh) * 2022-07-13 2023-07-25 苏州施安鼎泰生物医药技术有限公司 一种嘧啶并[5,4-c][2,6]萘啶衍生物及其制备方法以及药物组合物和应用
CN117402162A (zh) 2022-07-13 2024-01-16 江苏天士力帝益药业有限公司 Wee1抑制剂及其制备和用途
WO2024012549A1 (fr) * 2022-07-15 2024-01-18 映恩生物制药（苏州）有限公司 Composé hétérocyclique à cinq chaînons pyrimido, son procédé de préparation et son utilisation
CN119798282A (zh) * 2023-10-11 2025-04-11 智擎生技制药股份有限公司 基于稠合吡啶环的Myt1抑制剂
TW202519226A (zh) 2023-11-08 2025-05-16 美商艾克塞里克斯公司 使用抑制ｐｋｍｙｔ１之化合物治療癌症之方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
OA07174A (fr) 1981-08-24 1984-04-30 May & Baker Ltd Nouvelles imidazotétrazionones, leur préparation et les médicaments qui les contiennent.
JPS6019790A (ja) 1983-07-14 1985-01-31 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
JP2628707B2 (ja) * 1987-08-26 1997-07-09 三井製薬工業株式会社 ピリミジン類及びその薬学的に許容される塩類
US5223608A (en) 1987-08-28 1993-06-29 Eli Lilly And Company Process for and intermediates of 2',2'-difluoronucleosides
DK0547165T3 (da) 1990-09-28 2000-03-27 Smithkline Beecham Corp Fremgangsmåde til fremstilling af vandopløselige camptothecinanaloger såvel som forbindelserne 10-hydroxy-11-C(1-6)-alkoxyc
US5243050A (en) 1990-12-20 1993-09-07 North Carolina State University Alkylpyridone DE ring intermediates useful for the manufacture of camptothecin and camptothecin analogs
US5191082A (en) 1990-12-20 1993-03-02 North Carolina State University Camptothecin intermediate and method of making camptothecin intermediates
US5162532A (en) 1990-12-20 1992-11-10 North Carolina State University Intermediates and method of making camptothecin and camptothecin analogs
US5247089A (en) 1990-12-20 1993-09-21 North Carolina State University Method of making intermediates useful for the manufacture of camptothecin and camptothecin analogs
US5200524A (en) 1990-12-20 1993-04-06 North Carolina State University Camptothecin intermediates and method of making same
DE69233803D1 (de) 1992-10-28 2011-03-31 Genentech Inc Verwendung von vaskulären Endothelwachstumsfaktor-Antagonisten
JP3025602B2 (ja) 1993-05-21 2000-03-27 デビオファーム エス．アー． 光学的に高純度なシス−オキザラート（トランス−ｌ−１，２−シクロヘキサンジアミン）白金（ＩＩ）錯体の製造方法
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
JPH11507535A (ja) 1995-06-07 1999-07-06 イムクローン システムズ インコーポレイテッド 腫瘍の成長を抑制する抗体および抗体フラグメント類
JP3154399B2 (ja) 1996-07-04 2001-04-09 デビオファーム エス．アー． 白金化合物の製造方法
CZ27399A3 (cs) * 1999-01-26 2000-08-16 Ústav Experimentální Botaniky Av Čr Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv
SE0103649D0 (sv) 2001-11-01 2001-11-01 Astrazeneca Ab Therapeutic quinoline compounds
MXPA04010617A (es) 2002-04-26 2004-12-13 Warner Lambert Co Inhibidores de quinasa de puntos de control (wee1 y chk1).
UA80767C2 (en) 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
DE602004021558D1 (de) 2003-01-17 2009-07-30 Warner Lambert Co 2-aminopyridin-substituierteheterocyclen als inhibitoren der zellulären proliferation
AU2004212421B2 (en) * 2003-02-07 2009-08-20 Vertex Pharmaceuticals Incorporated Heteroaryl substituted pyrolls useful as inhibitors of protein kinases
US7320992B2 (en) * 2003-08-25 2008-01-22 Amgen Inc. Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use
US20050250836A1 (en) 2004-05-03 2005-11-10 Pfizer Inc Inhibitors of checkpoint kinases (Wee1 and Chk1)
CA2569530C (fr) 2004-07-01 2013-07-30 Daiichi Asubio Pharma Co.,Ltd. Derive de thienopyrazole ayant une activite d'inhibition de la pde 7
AU2006205851A1 (en) 2005-01-14 2006-07-20 Janssen Pharmaceutica N.V. 5-membered annelated heterocyclic pyrimidines as kinase inhibitors
WO2006091737A1 (fr) 2005-02-24 2006-08-31 Kemia, Inc. Modulateurs de l'activite de gsk-3
AR060635A1 (es) * 2006-04-27 2008-07-02 Banyu Pharma Co Ltd Derivados de 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-ona, composiciones farmaceuticas que los comprenden y su uso en el tratamiento del cancer

Also Published As

Publication number Publication date
ES2348751T3 (es) 2010-12-13
PE20080695A1 (es) 2008-06-28
DK2017278T3 (en) 2017-02-13
NO20084968L (no) 2008-11-26
BRPI0710081A2 (pt) 2011-08-02
PL2016080T3 (pl) 2011-03-31
EP2017278A1 (fr) 2009-01-21
EP2016080A4 (fr) 2009-05-13
ECSP088812A (es) 2008-11-27
MX2008013063A (es) 2008-12-16
EP2016080A1 (fr) 2009-01-21
AU2007244185A1 (en) 2007-11-08
HUE032987T2 (en) 2017-11-28
CN101432284B (zh) 2012-08-15
JP5167291B2 (ja) 2013-03-21
LT2017278T (lt) 2017-01-25
RU2008146759A (ru) 2010-06-10
HK1132498A1 (en) 2010-02-26
US20070254892A1 (en) 2007-11-01
RU2437885C2 (ru) 2011-12-27
WO2007126122A1 (fr) 2007-11-08
TW200811176A (en) 2008-03-01
CA2650119A1 (fr) 2007-11-08
US20110189130A1 (en) 2011-08-04
JP2010132689A (ja) 2010-06-17
US8791125B2 (en) 2014-07-29
GT200800211A (es) 2009-04-07
MY145408A (en) 2012-02-15
SI2016080T1 (sl) 2011-03-31
US7935708B2 (en) 2011-05-03
US20100063024A1 (en) 2010-03-11
DOP2007000084A (es) 2007-12-31
DE602007008085D1 (en) 2010-09-09
US20140303178A1 (en) 2014-10-09
KR101409161B1 (ko) 2014-06-19
KR20090017491A (ko) 2009-02-18
PL2017278T3 (pl) 2017-10-31
US7834019B2 (en) 2010-11-16
AU2007244185B2 (en) 2012-10-04
SV2009003060A (es) 2009-04-28
CA2650119C (fr) 2017-03-14
EP2016080B1 (fr) 2010-07-28
NO341617B1 (no) 2017-12-11
PT2017278T (pt) 2017-01-03
IL194367A (en) 2014-12-31
TWI409262B (zh) 2013-09-21
HRP20161763T1 (hr) 2017-02-24
EP2017278B1 (fr) 2016-11-02
EP2017278A4 (fr) 2009-04-22
PT2016080E (pt) 2010-10-14
CY1111069T1 (el) 2012-05-23
ZA200807748B (en) 2009-10-28
CN101432284A (zh) 2009-05-13
DK2016080T3 (da) 2010-11-22
CR10359A (es) 2009-02-19
ATE475662T1 (de) 2010-08-15
ES2609087T3 (es) 2017-04-18
JPWO2007126128A1 (ja) 2009-09-17
UA96152C2 (en) 2011-10-10
HRP20100563T1 (hr) 2010-11-30
CY1118526T1 (el) 2017-07-12
AR060635A1 (es) 2008-07-02
SI2017278T1 (sl) 2017-05-31
NZ571196A (en) 2011-03-31
IL194367A0 (en) 2009-08-03
WO2007126128A1 (fr) 2007-11-08
HN2008001532A (es) 2009-06-10
JP4513919B2 (ja) 2010-07-28

Similar Documents

Publication Publication Date Title
MA30428B1 (fr) Derives de dihydropyrazolopyrimidinones
MA31419B1 (fr) Derives de pyridine
MA30526B1 (fr) Inhibiteurs de prolyle hydroxylase
MA29926B1 (fr) Derives de pyrazine
MA28747B1 (fr) Dérivés de pyridine
MA30629B1 (fr) Derives de pyrazole servant d'inhibiteurs du cytochrome p450
NO20083207L (no) Inhibitorer av IAP
TN2009000428A1 (fr) Derives de sulfonylamides destines au traitement d'une croissance cellulaire anormale
MA31444B1 (fr) Agents de lutte contre les parasites invertebres
MA31894B1 (fr) Composes organiques
MA30075B1 (fr) Derives de pyrimidine pour le traitement d'une croissance cellulaire anormale
SG132672A1 (en) 1,4-disubstituted isoquinilone derivatives as raf-kinase inhibitors useful for the treatment of proliferative diseases
MA30911B1 (fr) Nouveaux derives de sulfonamide en tant qu'antagonistes de bradykinine
MA31311B1 (fr) Dérivés d'indazole substitués par oxadiazole, destinés à être utilisés comme agonistes de la sphingosine 1-phosphate (s1p)
EA200601830A1 (ru) Ортозамещённые арильные или гетероарильные амидные соединения
MA35112B1 (fr) Inhibiteurs de tyrosine kinase de bruton
MA32135B1 (fr) Inhibiteurs de pim kinase et leurs procedes d'utilisation
TN2009000204A1 (fr) Spirocetones servant d'inhibiteurs d'acetyl-coa-carboxylase
TNSN07275A1 (fr) Derives de triazole substitues, servant d'antagonistes d'ocytocine
MA32965B1 (fr) Derives de sulfonamides
TN2010000248A1 (fr) Derives d'indolinone et procede pour leur fabrication
MA30228B1 (fr) Pipéridinoylpyrrolidines agonistes du récepteur de mélanocortine de type 4
TNSN07178A1 (fr) N-sulfonylaminobenzyl-2-phenoxy-acetamides substitues
MXPA05009535A (es) Compuestos de acido n - alquil - hidroxamico - isoindolilo y sus usos farmaceuticos.
MA30377B1 (fr) Derives de quinoline et leur emploi en tant que pesticides.